Objective: The aim of this work was to assess the prognostic value of absolute N-terminal-proeB-type natriuretic peptide (NT-proBNP) concentration in combination with changes during admission because of acute heart failure (AHF) and early after hospital discharge. Background: In AHF, readmission and mortality rates are high. Identifying those at highest risk for events early after hospital discharge might help to select patients in need of intensive outpatient monitoring. Methods and results: We evaluated the prognostic value of NT-proBNP concentration on admission, at discharge, 1 month after hospital discharge and change over time in 309 patients included in the PRIMA (Can PRo-brain-natriuretic peptide guided therapy of chronic heart failure IMprove heart fAilure morbidity and mortality?) study. Primary outcome measures were mortality and the combined end point of heart failure (HF) readmission or mortality. In a multivariate Cox regression analysis, change in NT-proBNP concentration during admission, change from discharge to 1 month after discharge, and the absolute NT-proBNP concentration at 1 month after discharge were of independent prognostic value for both end points (hazard ratios for HF readmission or mortality: 1.71, 95% confidence interval [CI] 1.13e2.60, Wald 6.4 [P 5 .011] versus 2.71, 95% CI 1.76e4.17, Wald 20.5 [P ! .001] versus 1.81, 95% CI 1.13e2.89, Wald 6.1 [P 5 .014], respectively. Conclusions: Knowledge of change in NT-proBNP concentration during admission because of AHF in combination with change early after discharge and the absolute NT-proBNP concentration at 1 month after discharge allows accurate risk stratification. (J Cardiac Fail 2014;20:881e890) 
Acute heart failure (HF) is not only associated with a high in-hospital mortality rate, 1 but short-and long-term prognosis after hospital discharge also remains poor, with high mortality and readmission rates. 2, 3 Therefore, post-discharge risk stratification is important because it may help to identify those patients in need of intensive outpatient monitoring and treatment. Unfortunately, even for trained clinicians it can be quite challenging to accurately stratify risk in those who have recently been admitted because of acute HF. During the last decade, B-type natriuretic peptide (BNP) and its cleavage equivalent N-terminal pro-BNP (NT-proBNP) have proved to be powerful prognostic markers in both acute and chronic HF. In acute HF, both pre-discharge (NT-pro)BNP concentration and decrease in NT-proBNP during hospital admission are related to outcome after hospital discharge. 4, 5 Also in chronic HF, not only does a single measurement of natriuretic peptides reflect risk, but variation in natriuretic peptides also adds to prognostic assessment. 6 However, the prognostic value of change in NT-proBNP concentration 1 month after admission because of acute HF has not yet been evaluated. Furthermore, the incremental value of serial NT-proBNP measurements during admission and early after hospital discharge has not yet been assessed. Therefore, we sought to identify which NT-proBNP parameters during admission and early after discharge (ie, absolute NT-proBNP concentration at admission, discharge, 1 month after hospital discharge, change in NT-proBNP during admission [''inpatient change''], and change in NT-proBNP concentration between discharge and 1 month after discharge [''early outpatient change'']) were of independent prognostic importance. Finally, because biologic variation of NT-proBNP in HF has been reported to be high in chronic HF, 7 one might conclude that only large early outpatient changes in NT-proBNP have prognostic impact. Therefore, we also assessed the prognostic impact of relatively small early outpatient changes in NT-proBNP (ie, changes up to 30%).
Methods

Study Design and Study Population
This was a post hoc analysis of patients included in the PRIMA (Can PRo-brain-natriuretic peptide guided therapy of chronic heart failure IMprove heart fAilure morbidity and mortality?) study, a prospective randomized multicenter study assessing the effect of management of chronic HF guided by individual NT-proBNP targets. 8 Inclusion criteria have been published previously. 8 In short, patients were included during hospital admission for acute HF. NT-proBNP concentration at admission was required to be $1,700 pg/mL, and included patients also needed to demonstrate a decrease in NT-proBNP concentration of at least 10% with a minimum of 850 pg/mL during admission. At discharge, patients were randomized to outpatient treatment that was either clinically guided where NT-proBNP was measured but not revealed to the physician, or to outpatient treatment where NT-proBNP levels were provided to guide therapy. The follow-up period was up to 2 years. For the present analysis, patients with outpatient NT-proBNP concentration available 1 month after hospital discharge were included. As a result, patients not attending the outpatient clinic 1 month after discharge (because of death, readmission, or any other reason) were not included. All events occurring before the outpatient visit 1 month after hospital discharge were censored.
Definition of Study End Points
Primary outcome measures were mortality and the combined end point of HF readmission or mortality within the follow-up period after the outpatient visit 1 month after discharge. Secondary end points encompassed the primary end points reached at 90, 180, and 365 days of follow-up.
Statistical Analysis
Data are presented as frequencies, mean 6 SD, or median (interquartile range [IQR] ). Comparisons between groups were performed with the use of Fischer exact test for categoric data and 1-way analysis of variance or Kruskal-Wallis H test for continuous data, as appropriate. Glomerular filtration rate was estimated (eGFR) with the use of the Modified Diet in Renal Disease equation. 9 Univariate Cox proportional hazard regression analysis was performed to assess clinical covariates associated with mortality. Spearman rank correlations where used to test correlations among the various NT-proBNP parameters. Multivariate Cox proportional hazard regression analysis was performed with the use of all covariates associated with outcome, except renal function and NT-proBNP concentration, to assess the clinical model. Variables were added in a stepwise fashion with P ! .05 and P ! .1 as the cutoffs for entry or retention, respectively. After assessment of the clinical model, renal function (eGFR !30 mL/min, eGFR 30e60 mL/min, or eGFR O60 mL/min) was added to form the reference model. To assess the independent prognostic value of NT-proBNP concentration on admission, at discharge, inpatient change, early outpatient change, and NT-proBNP concentration at 1 month after hospital discharge, these parameters were added to the reference model in a stepwise fashion to form the final NT-proBNP model.
Model accuracy and discrimination were evaluated for both mortality and the combined end point of HF readmission or mortality within 1 year of follow-up by (i) c-statistic, a measure of the area under the receiver operating characteristic curve (AUC) and (ii) integrated discrimination improvement (IDI). Calculations were done with the use of IBM SPSS Statistics 21.0 (IBM, Armonk, New York) and Medcalc 13.3.3.0 (Medcalc Software, Ostend, Belgium).
Composite NT-proBNP Score
Independent predictive NT-proBNP parameters were used to form the composite NT-proBNP score. This was done by giving each independent prognostic NT-proBNP parameter 1 point. To assess the prognostic impact of the composite NT-proBNP score, 90-, 180, and 365-day mortality and the combined end point of HF readmission or mortality were calculated for every composite NT-proBNP score category. Furthermore, Kaplan-Meier survival curves were assessed and compared with the use of the log-rank test.
Finally the value of relatively small early outpatient changes in NT-proBNP (ie, decrease vs increase in NT-proBNP concentration of !30%) was assessed in a multivariate manner.
Results
Patient Characteristics
In 309 out of 345 patients included in the PRIMA study, NT-proBNP levels at admission, discharge, and 1 month after hospital discharge were available. Patient characteristics at baseline and 1 month after hospital discharge are presented in Table 1 . Patients were overall elderly and predominantly male, more than one-half had coronary artery disease, and about one-half had an ischemic etiology of HF. At admission because of acute HF, median NT-proBNP concentration was clearly elevated, and during NT-proBNP, N-terminal proeB-type natriuretic peptide; BMI, body mass index; TIA, transient ischemic attack; COPD, chronic obstructive pulmonary disease; PCI, percutaneous coronary intervention; CABG, coronary artery bypass grafting; ICD, implantable cardiac defibrillator; HF, heart failure; NYHA, New York Heart Association; LVEF, left ventricular ejection fraction; eGFR, estimated glomerular filtration rate; ACE, angiotensin-converting enzyme; ARB, angiotensin receptor blocker.
Values are expressed as n (%), mean (SD), or median (interquartile range).
admission the median decrease in NT-proBNP concentration was O60%. One month after hospital discharge, median NT-proBNP concentration was 2,538 pg/mL.
Prediction of Outcome
Median time from hospital discharge to the outpatient visit 1 month after discharge was 30 days (IQR 27e36 days), with a median follow-up duration of 675 days (IQR 472e700 days) after this visit.
Within the follow-up period, 83 patients died (26.9%) and 131 patients reached the combined end point of HF readmission or mortality (42.4%). Both mortality and the combined end point at 90, 180, and 365 days in the overall population are presented in Table 2 . In univariate Cox regression analyses, all NT-proBNP parameters except NT-proBNP concentration at admission were highly associated with mortality (Table 3 ).
Comparison With Patients Not Included in This Analysis
In 309 of 345 patients, NT-proBNP concentration 1 month after hospital discharge was available. Of the patients not included for the present analysis, 5 died within 30 days after hospital discharge and 6 had reached the combined end point of HF-related readmission or mortality. After exclusion of these patients, there was a trend toward increased mortality in patients with no NT-proBNP concentration available 1 month after hospital discharge compared to those with NT-proBNP concentration available (HR 1.75, 95% CI 0.96e3.21; P 5 .070). However, no difference was seen in combined end point (HR 1.14, 95% CI 0.66e1.97; P 5 .65).
Correlation Among NT-proBNP Parameters
Correlations among NT-proBNP parameters are depicted in Supplemental Table 1 . No correlation existed between inpatient change in NT-proBNP concentration and early outpatient change (r 5 À0.01; P 5 .815). Modest correlations existed between NT-proBNP concentration 1 month after hospital discharge and both inpatient and early outpatient change in NT-proBNP concentration, with strongest correlation being present between inpatient change and NT-proBNP concentration at 1 month follow-up (r 5 0.56; P ! .001). However, we found strong correlations between the absolute NT-proBNP concentration at admission, discharge, and 1 month after hospital discharge, with strongest correlation between NT-proBNP at admission and at discharge (r 5 0.79; P ! .0001).
Multivariate Analysis
Based on the multivariate analysis on clinical risk factors, previous episode of HF, ischemic etiology of HF, age, and mean arterial pressure (MAP) were included in the clinical model. In addition, renal function at 1 month after discharge (eGFR !30 mL/min, 30e60 mL/min, or O60 mL/min) was added to form the reference model. Adding eGFR as a continuous instead of a categoric variable did not change the predictive performance of the reference model.
When adding the NT-proBNP parameters to this reference model, inpatient change in NT-proBNP concentration (decrease below vs above the median), early outpatient change in NT-proBNP (increase vs decrease), and NT-proBNP concentration at 1 month after discharge (above vs below the median) remained independent prognostic markers, whereas the absolute NT-proBNP concentration at discharge dropped out of the model ( Table 3) .
The final NT-proBNP prognostic model therefore consisted of the reference model plus inpatient change in NT-proBNP concentration, early outpatient change in NT-proBNP, and the absolute NT-proBNP concentration 1 month after discharge.
Model accuracy and discrimination of the NT-proBNP prognostic model for 1-year mortality and 1-year HF readmission or mortality are presented in Table 4 . Model accuracy and discrimination for HF readmission and mortality reached a c-statistic of 0.85 (95% CI 0.81e0.90), with excellent calibration (Hosmer-Lemeshow: P 5 .77), and had significantly better model performance than models with 1 NT-proBNP parameter (IDI ranging from 6% to 13% [P ! .001], improvement in c-statistic ranging from 0.3 to 0.7 [P ! .05]; Table 4 ). For mortality, the same trend was seen (Table 4 ). Abbreviations as in Table 1 .
Composite NT-proBNP Score
By combining the independent prognostic NT-proBNP parameters (ie, inpatient decrease in NT-proBNP concentration below vs above the median, early outpatient increase vs decrease in NT-proBNP, and NT-proBNP concentration at 1 month after discharge above vs below the median), a composite NT-proBNP score was formed by giving 1 point for each parameter that was elevated. This resulted in patients being divided into 4 groups: from 0 parameters elevated (group 1) to 3 parameters elevated (group 4). Baseline characteristics of all groups are depicted in Table 1 . With increasing NT-proBNP parameters elevated, patients were older, more often had a previous episode of heart failure, and more often had ischemic cause of HF. Increasing composite NT-proBNP score was also associated with lower blood pressure and more impaired renal function. Interestingly left ventricular ejection fraction did not differ among the 4 groups.
The composite NT-proBNP score strongly predicted events: both short-and long-term prognosis differed significantly among the 4 groups regarding mortality and the combined end point HF-related readmission or mortality ( Table 2 ; Fig. 1 ). All patients without NT-proBNP parameters elevated (group 1; n 5 62) survived 1 year follow-up, whereas 41% of patients with all 3 NT-proBNP parameters elevated (group 4; n 5 70) died within 1 year of follow-up.
Prognostic Impact of Small Outpatient Changes in NT-proBNP Concentration
Small changes in NT-proBNP concentration are associated with outcome. In multivariate analysis including the reference model, inpatient change in NT-proBNP, and NT-proBNP concentration at 1 month after discharge, early outpatient increase in NT-proBNP concentration !30% was associated with worse outcome compared with early outpatient decrease in NT-proBNP !30% (HR for mortality 2.05, 95% CI 1.02e4.13, Wald 4.1 [P 5 .04], HR for the combined end point 2.59, 95% CI 1.45e4.64, Wald 10.2 [P 5 .001]). Interestingly, there was no significant difference in mortality or the combined end point between patients with an early outpatient decrease of !30% vs O30% (HR for the combined end point 1.04, 95% CI 0.50e2.18, Wald 0.01; P 5 .914). Likewise, an increase in NTproBNP concentration of !30% yielded a clinically similar hazard for events compared with an increase O30% (HR for the combined end point 0.96, 95% CI 0.62e1.47, Wald 0.04; P 5 .837).
Prognostic Value of NT-proBNP Parameters in Both Treatment Arms of the PRIMA Study
Because in one-half of the patients included in the PRIMA-study the treating physician was not blinded to the outpatient NT-proBNP concentration, knowledge of NT-proBNP might have influenced the decision whether to admit a patient or not. However, in multivariate analysis correcting for the reference model and randomization group, inpatient change in NT-proBNP, early outpatient change in NT-proBNP, and NT-proBNP concentration 1 month after hospital discharge remained independent prognostic factors (Supplemental Table 2 ). Moreover, in both treatment arms all 3 NT-proBNP parameters were of prognostic importance (Supplemental Figs. 1 and 2 ).
Discussion
In this study, we evaluated the prognostic value of serial NT-proBNP measurements during and early after an admission for acute HF. We demonstrated that the a) inpatient change in NT-proBNP concentration, b) early outpatient change, and c) absolute NT-proBNP concentration at 1 month after discharge were each independent prognosticators and together enabled accurate short-and long-term outpatient risk assessment. Importantly, even small changes in the early outpatient phase (ie, !30% change in NT-proBNP) had prognostic meaning.
Inpatient NT-proBNP Measurements
Although the natriuretic peptide concentration at admission for acute HF predicts inpatient mortality, 10 its prognostic effect after discharge seems to be small. This is in sharp contrast to NT-proBNP concentration at discharge and changes in NT-proBNP during admission, which both seem to be better predictors of outcome. For example, Bettencourt et al 4 demonstrated that a NT-proBNP level O6,779 pg/mL at hospital admission predicted a nonsignificant trend toward hazard of readmission or death, but the NT-proBNP concentration at discharge of 4,137 pg/mL was a much stronger predictor of hazard (log rank P for cumulative hospitalization-free survival: !.001). They furthermore found that inpatient decrease in NT-proBNP values of $30% was related to favorable outcome. In addition, Kubler et al 11 demonstrated that the optimal cutoff value for inpatient decrease in NT-proBNP was 65%. A decrease in NT-proBNP concentration in acutely decompensated HF is related to hemodynamic improvement 12 and is thereby a marker of success of HF treatment during admission. It is therefore not surprising that the extent of decrease in NT-proBNP during admission reflects outpatient outcome after discharge. Our findings go beyond these conclusions, showing that inpatient changes in NT-proBNP are of prognostic importance independently from early outpatient changes as well as independently from NT-proBNP levels measured at 1 month after hospital discharge.
In contrast to inpatient change in NT-proBNP, NT-proBNP concentration at discharge failed to retain prognostic impact in multivariate analysis.
The presence of strong correlations between the absolute NT-proBNP concentrations will certainly have influenced the selection process in multivariate analysis that led to the uptake of NT-proBNP concentration at 1 month after hospital discharge over NT-proBNP at hospital discharge (Supplemental Table 2 ). However, the fact that NT-proBNP concentration 1 month after hospital discharge remained the strongest prognostic NT-proBNP value is not surprising, because it is the most recent measurement. This is also shown by univariate analysis: NT-proBNP concentration 1 month after hospital discharge yielded the highest Wald score for mortality (15.6 vs 15.2 for NT-proBNP at discharge). The prognostic value of changes in NT-proBNP at the outpatient clinic compared with only a single measurement seems to depend on the outpatient setting. One study reported that absolute NT-proBNP concentration at 3 months after acute HF admission had more predictive power in multivariate analysis than percentage change within 3 months (chi-square value of log NT-proBNP after 3 months 41.5, compared with 7.5 for NT-proBNP percentage change). 13 Also in chronic stable HF, the prognostic power of absolute NT-proBNP concentration appears to be superior to relative changes in NT-proBNP. A subanalysis of the Val-HeFT trial, for example, demonstrated a higher prognostic discrimination of a single determination of NT-proBNP compared with relative changes after 4-month follow-up (AUC 0.70 vs 0.60, respectively). 6 Changes in NT-proBNP concentration seem to have higher prognostic impact in outpatient destabilized HF; Bayes-Genis et al, for example, reported a 21% reduction in events for every 10% decrease in NT-proBNP within 2 weeks. 14 In contrast, the absolute NT-proBNP concentration at 2 weeks lost its predictive power in multivariate analysis.
We show that 1 month after hospital discharge, change in NT-proBNP has prognostic power similar to the absolute NT-proBNP concentration measured at 1 month for prediction of mortality (Table 3 ). For prediction of the combined end point of HF readmission or mortality, early outpatient change in NT-proBNP is clearly superior to the absolute concentration at 1 month (Wald 20.5 vs 6.1, respectively; Table 4 ). Thus it seems that in patients at highest risk for events (outpatient destabilized HF and early after admission because of acute HF), a change in NT-proBNP concentration between 2 measurements at relatively short interval is an important predictor for events, and clinical stability cannot be assumed by only 1 NT-proBNP measurement.
Prognostic Importance of Small Changes in NT-proBNP Concentration 1 Month After Hospital Discharge
Changes in natriuretic peptide concentrations may reflect changes in cardiac wall stress and cardiac performance, but may also depend on the biologic variability of these biomarkers. For NT-proBNP, biologic variability has been assessed in chronic HF patients at different time intervals (within-day, week-to-week, 1 to 3 months, and year-to year 7,15e19 ). Short term biologic variability in terms of reference change values (RCVs) differed widely among studies published, varying from 23% 19 to 98%, 7 suggesting that changes in NT-proBNP concentration even up to 100% may be safely accepted. Our finding that small changes in NT-proBNP concentration (ie, !30%) early after hospital discharge are of prognostic importance challenges these interpretations of so-called ''biologic variability'' of NT-proBNP. The high RCVs found in the previously mentioned studies are controversial because they appear to be related to the skewed distribution of measured NT-proBNP values and improve after normalizing transformation of the data. 16 Also, median NT-proBNP concentrations in studies assessing biologic variability of NT-proBNP were relatively low (579e1,323 pg/mL) 15, 16 and biologic variability has been shown to decrease with elevating NT-proBNP concentration. 15 Furthermore patient numbers were limited in these studies (20e78 patients). 18, 19 Most importantly, these studies assumed that their patients were in a stable condition based on clinical characteristics and on their stability in the past, but did not take into account the long-term survival after measurement of NT-proBNP concentration. Moreover, it was assumed that clinical stability can easily be assessed without in-depth diagnostic testing, which is most likely not the case. Therefore, objective evidence of clinical stability was lacking and subclinical changes in NT-proBNP concentration might have actually been an earlydsubclinicaldsign of worsening HF. Indeed, in line with this reasoning, the only study assessing short term biologic variability of NT-proBNP with a follow-up period of 6 months showed the lowest RVC, 23%. 19 Composite NT-proBNP Score and Implications for Clinical Practice A composite NT-proBNP score that combines inpatient change in NT-proBNP with early outpatient change and the absolute NT-proBNP concentration 1 month after hospital discharge identified HF patients at very low (1.6%), intermediate (8.5%e16.9%), and high (38.6%) risk for early readmission or mortality. The prognostic impact remained after one year follow-up. The composite NT-proBNP score has been designed to illustrate the incremental information from the different NT-proBNP measurements. Because the cutpoints for the NTproBNP parameters were defined by the distribution within the PRIMA study, application of these cutpoints cannot be used in clinical practice until validation analysis has been performed. Furthermore, whether knowledge of the individual risk for events would lead to reduction in morbidity and mortality remains to be assessed by future trials and cannot be answered by the present study. However, it seems plausible that patients at highest risk for events might benefit most from intensified outpatient follow-up in combination with increased prescription of evidence-based HF medication, such as angiotensinconverting enzyme inhibitors, beta-blockers, and aldosterone antagonists.
Recent trials assessing the effect of natriuretic peptidee guided therapy in HF that randomized patients into 3 treatment arms (ie, regular outpatient care vs intensified outpatient care with or without knowledge of natriuretic peptide concentration) have shown that intensified outpatient care leads to a decrease in HF related readmissions and mortality compared to usual care. 20, 21 The BATTLE-SCARRED (NT-proBNPeAssisted Treatment to Lessen Serial Cardiac Readmissions and Death) trial, eg, demonstrated 1-year mortality being lower in the intensified outpatient treatment group (9.1%) compared with usual care (18.9%; P 5 .03). 21 Furthermore, in all 4 studies demonstrating a positive effect of natriuretic peptideeguided therapy, 20,22e24 a marked increase in evidence-based HF medication was seen in the natriuretic peptideeguided arm compared with the usual care arm. Thus, intensified treatment in combination with increase in evidence-based HF medication appears to lead to better outcome. In 2 of these 4 trials, patients allocated to the NT-proBNPeguided therapy arm had fewer prescription of loop diuretics compared with usual care management. 20, 22 In the PRIMA study, which failed to demonstrate a significant reduction in end points by NT-proBNPeguided therapy, outpatient elevated NT-proBNP levels led most frequently to an increase in diuretic dosage (O40%). 8 Given the association between loop diuretics and worsening of renal function, neurohumoral activation, and adverse outcome in HF, 25 the use of diuretics is recommended to be limited to achieve and maintain an euvolemic state with the lowest achievable dose. 26 Combining individual risk assessment with the previously mentioned findings from the recent natriuretic peptideeguided therapy studies might lead to an early outpatient individual treatment approach that should be confirmed in future trials. It is assumed that if individual risk for events is low (ie, low composite NT-proBNP score) and a patient is clinically euvolemic, then diuretic dosage should be lowered and outpatient follow-up might be directed to the primary care. If individual risk is high (ie, high composite NT-proBNP score) and the patient is clinically euvolemic, then outpatient follow-up should be intensified at a dedicated outpatient HF clinic with extra attention being paid to compliance and intensified prescription of evidence-based HF medication. If clinical signs of overt or worsening HF occur, diuretic dosage should be increased first, followed by intensification of evidencebased HF medication. However, as already said, large randomized trials are needed to further clarify this issue.
Study Limitations
There are some limitations to the present study. It should be emphasized that the composite NT-proBNP score was calculated to visualize the incremental value of serial NT-proBNP measurements during and early after admission because of acute HF. It was not the intention to develop a risk score that can be used in clinical practice. The NT-proBNP cutpoints were defined from patients included in the PRIMA study. To be included in the PRIMA study, NT-proBNP concentration during admission needed to decrease $10% with a minimum of 850 pg/mL. Therefore, we cannot extrapolate our results to patients with a smaller decrease, or an increase in NT-proBNP concentration, during admission. Also, as this study is a post hoc analysis, results remain to be validated by another, preferably larger, prospective study.
Conclusion
For adequate individual risk assessment early after hospital discharge, knowledge of serial NT-proBNP values is important. Early changes in NT-proBNP concentration after admission because of HF, the extent of decrease in NT-proBNP concentration during admission and the absolute NT-proBNP concentration 1 month after hospital discharge are independent prognostic parameters. They may help to further individualize risk of readmission because of HF or mortality. Even relative small early outpatient changes in NT-proBNP are associated with outcome, suggesting that biologic variability is small and that changes in these levels do reflect underlying pathophysiologic processes. Knowledge of individual risk might lead to an individualized treatment approach, and the effect of such an approach should be assessed in future randomized trials.
